Current Research Studies

Cancer - AINV18P1: Phase 1 Study of Palbociclib, A CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Condition or Therapy:

B- or T-lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Category:

Cancer and Blood Disorders

What is the goal of this study?

The goal of this study is to determine the maximum dose of palbociclib given with re-induction chemotherapy in pediatric patients with relapsed B- or T-lineage ALL/LL.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are between 12 months and 31 years old
  • Have recurrent or refractory B- or T- lineage lymphoblastic leukemia and lymphoma

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Childrens Main Hospital Campus

Principal Investigator:

Dr. Adam Lamble